The evaluation of drug rechallenge: the casopitant Phase III program.
Hunt
Christine M
CM
GlaxoSmithKline, RTP, Durham, NC 27709, USA. Christine.M.Hunt@gsk.com
Papay
Julie I
JI
Rich
Donna S
DS
Abissi
Christopher J
CJ
Russo
Mark W
MW